Search results for: 'Software-as-a-Service china'

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transpire ...

20 Jan 2025  |  Global  |  Market Research

Global Cardiac Biomarkers Diagnostics Industry, 2024-2029

Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics

Infographics

×

The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highligh...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...